Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Immutep ADS Representing 10 Ord Shs IMMP

Healthcare Biotechnology
Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to... see more

Recent & Breaking News (NDAQ:IMMP)

Positive Initial Clinical Data Reported from Immutep's Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma

GlobeNewswire 5 days ago

Immutep Quarterly Activities Report Q3 FY24

GlobeNewswire 8 days ago

Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

GlobeNewswire 13 days ago

Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761

GlobeNewswire April 18, 2024

Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

GlobeNewswire April 17, 2024

Immutep Announces First Clinical Data from 90mg Dosing of Efti

GlobeNewswire March 5, 2024

Immutep Quarterly Activities Report Q2 FY24

GlobeNewswire January 30, 2024

First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer

GlobeNewswire January 4, 2024

Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

GlobeNewswire December 21, 2023

Immutep Receives A$2.6 million R&D Tax Incentive from French Government

GlobeNewswire December 7, 2023

Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial

GlobeNewswire November 22, 2023

Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

GlobeNewswire November 9, 2023

Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer

GlobeNewswire November 6, 2023

Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer

GlobeNewswire November 3, 2023

Immutep to Participate in November Investor Events

GlobeNewswire November 2, 2023

Immutep Quarterly Activities Report Q1 FY24

GlobeNewswire October 31, 2023

Immutep receives ~A$1.13 million R&D Tax Incentive

GlobeNewswire October 25, 2023

Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023

GlobeNewswire October 24, 2023

Immutep's Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer

GlobeNewswire October 23, 2023

Immutep Announces Publication of Abstracts at ESMO Congress 2023

GlobeNewswire October 16, 2023